Publications in collaboration with researchers from Hospital Universitario Puerta de Hierro (449)

2024

  1. Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry

    Archivos de Bronconeumologia

  2. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

  3. Biallelic Loss of Function Variants in Myocardial Zonula Adherens Protein Gene (MYZAP) Cause a Severe Recessive Form of Dilated Cardiomyopathy

    Circulation: Heart Failure

  4. Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 88-94

  5. Consenso del grupo de trabajo de los trastornos de la conducta alimentaria de SENPE (GTTCA-SENPE). Evaluación y tratamiento médico-nutricional en la anorexia nerviosa. Actualización 2023

    Nutricion hospitalaria, Vol. 41, Núm. 1, pp. 1-60

  6. Cost-effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalemia in patients with chronic kidney disease or heart failure in Spain

    Nefrologia, Vol. 44, Núm. 5, pp. 709-720

  7. Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry

    Lung Cancer, Vol. 190

  8. Diagnosis and treatment of myocarditis and inflammatory cardiomyopathy. Consensus document of the SEC-Working Group on Myocarditis

    Revista Espanola de Cardiologia, Vol. 77, Núm. 8, pp. 667-679

  9. Difficulties on the access to innovative targeted therapies for lung cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612

  10. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

    Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851

  11. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

    Journal of the American Heart Association, Vol. 13, Núm. 15, pp. e035993

  12. Double somatic mosaicism in Marfan syndrome

    American Journal of Medical Genetics, Part A

  13. ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-related cancer

  14. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466

  15. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

    Journal of Cardiac Failure

  16. European Society for Organ Transplantation (ESOT) Consensus Statement on the Use of Non-invasive Biomarkers for Cardiothoracic Transplant Rejection Surveillance

    Transplant International , Vol. 37

  17. Executive Summary of the Spanish Society of Anesthesiology, Reanimation and Pain Therapy (SEDAR), Spanish Society of Emergency and Emergency Medicine (SEMES) and Spanish Society of Otolaryngology, Head and Neck Surgery (SEORL-CCC) Guideline for difficult airway management

    Acta Otorrinolaringologica Espanola, Vol. 75, Núm. 6, pp. 382-399

  18. Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk

    Lung Cancer, Vol. 195

  19. Glucose metabolism outcomes after pituitary surgery in patients with acromegaly

    Pituitary, Vol. 27, Núm. 5, pp. 497-506

  20. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

    Journal of the American College of Cardiology, Vol. 84, Núm. 19, pp. 1821-1831